Research Reports

Key takeaways

Revenue increased 95.8% YoY to $141K from $72K, driven by Zenas collaboration uptick amid related party ties.

Operating loss deepened 23.8% YoY to -$116.2M from -$93.9M, reflecting intensified clinical trial investments.

Net loss expanded 20.7% YoY to -$104.9M from -$86.9M as expenses outpaced modest revenue gains.

Elegrobart safety study enrollment hit 321 patients versus 284 target by October 2025, exceeding goals due to demand but signaling elevated funding requirements.

Future viability hinges on raising capital to sustain operations and advance clinical programs, per management.

Full analysis

Viridian Therapeutics reported Q1 FY2026 results reflecting heavy clinical investment in its TED pipeline, with revenue rising 95.8% year-over-year to $141K from $72K, primarily from the Zenas collaboration—a related party transaction due to shared investor Fairmount Funds' stake and board ties. This uptick underscores partnership momentum but remains dwarfed by operating expenses, driving operating income to -$116.2M, a 23.8% worsening from -$93.9M prior year, as the company progresses veligrotug toward potential approval and advances elegrobart.

Net income followed suit, widening 20.7% to -$104.9M from -$86.9M, consistent with the company's history of losses and limited operating track record. Management notes anticipation of significant ongoing losses, with viability dependent on generating operating cash or raising capital to fund trials. Additional strategic alliances may be pursued to support the clinical development program.

VRDN · Viridian Therapeutics, Inc.

Summary

Key takeaways

Full analysis